Showing 6681-6690 of 8649 results for "".
- Opthea Names Quinton Oswald and Susan Orr, OD, to its Board of Directorshttps://modernod.com/news/opthea-names-quinton-oswald-and-susan-orr-od-to-its-board-of-directors/2480790/Opthea announced the appointment of Quinton Oswald and Susan Orr, OD, to its Board of Directors, effective immediately following election at a General Meeting of Shareholders on April 21st, 2022. Mr. Oswald and Dr. Orr have deep experience leading biotech companies and launching c
- CorneaGen Releases New DSEK Surgery Device to Help Streamline DSEK Surgerieshttps://modernod.com/news/corneagen-advances-next-generation-of-dsek-surgery-innovation/2480789/CorneaGen announced the release of the EndoSerter-PL, a new FDA approved, single-use graft insertion device preloaded with processed tissue to help streamline DSEK surgeries. “We’re incredibly excited to deliver the EndoSerter-PL, our latest innovation in
- Genentech Launches Retina Study in Underrepresented Patient Populationshttps://modernod.com/news/genentech-launches-first-retina-study-in-underrepresented-patient-populations/2480747/
- IAPB Introduces ‘Focus On Child Eye Health’https://modernod.com/news/iapb-introduces-focus-on-child-eye-health/2480729/Over the last few years, The International Agency for the Prevention of Blindness (IAPB) reached the world’s thought leaders with its ‘Focus On Glaucoma’ and ‘Focus On Diabetes’ series. The organization is excited to expand thi
- Evmann Creates Roadmap to Facilitate its Development into a €1 Billion Global Companyhttps://modernod.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/Dutch Evmann Investments Holding, the parent company of VSY Biotechnology, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a "unicorn" company. "Unicorn" is a term used in the venture capital industry to describe 
- Visus Therapeutics Initiates Phase 3 Pivotal Trials of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-initiates-phase-3-pivotal-trials-of-brimochol-pf-for-the-treatment-of-presbyopia/2480710/Visus Therapeutics announced the launch of the first of two pivotal phase 3 trials (BRIO-I and BRIO-II) for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. The initiation of the BRIO trials follows compelling topline data from th
- Bryan Wolynski Named Chief Technology Officer at Lighthouse Guildhttps://modernod.com/news/bryan-wolynski-named-chief-technology-officer-at-lighthouse-guild/2480702/Bryan Wolynski, OD, FAAO, has been named Chief Technology Officer at Lighthouse Guild. Dr. Wolynski will oversee all technology resources for the organization, including the recently opened Lighthouse Guild Technology Center, and will develop strategies to bring the latest technological advances
- Ocuphire Completes Enrollment in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathyhttps://modernod.com/news/ocuphire-completes-enrollment-in-24-week-zeta-1-phase-2b-trial-of-oral-apx3330-for-the-treatment-of-diabetic-retinopathy/2480700/
- Study Shows Eyenovia's Optejet Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutionshttps://modernod.com/news/study-shows-eyenovias-optejet-delivery-technology-reduces-conjunctival-cell-toxicity-from-preserved-ophthalmic-solutions/2480698/Eyenovia announced positive results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface damage from latanoprost+benzalkonium chloride (BAK) treatment administered via
- Alcon Debuts Dailies Total1 for Astigmatism, Other Eye Care Innovations at SECO 2022https://modernod.com/news/alcon-debuts-dailies-total1-for-astigmatism-other-eye-care-innovations-at-seco-2022/2480694/